MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Becton Dickinson and Co

Suletud

SektorTervishoid

225.91 -1.35

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

225.53

Max

228.96

Põhinäitajad

By Trading Economics

Sissetulek

-118M

303M

Müük

-272M

5.2B

P/E

Sektori keskmine

38.627

63.778

Aktsiakasum

3.43

Dividenditootlus

1.74

Kasumimarginaal

5.863

Töötajad

70,000

EBITDA

-1.3B

453M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+19.62% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.74%

2.39%

Järgmine tulemuste avaldamine

1. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-6.1B

66B

Eelmine avamishind

227.26

Eelmine sulgemishind

225.91

Uudiste sentiment

By Acuity

11%

89%

18 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Becton Dickinson and Co Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. veebr 2025, 22:09 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business

7. nov 2024, 12:59 UTC

Tulu

Becton Dickinson Profit Rises as Acquisition Buoys Sales - Update

7. nov 2024, 12:56 UTC

Tulu

Becton Dickinson Fiscal 4Q Profit Rises as Acquisition Buoys Sales

1. aug 2024, 11:08 UTC

Tulu

Becton 3Q Adjusted Earnings Top Views But International Sales Weigh on FY24 Outlook

3. juuni 2024, 11:18 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash

5. veebr 2025, 21:56 UTC

Tulu

Correct: Becton Dickinson Sees 2025 Adj EPS $14.30-Adj EPS $14.60 >BDX

5. veebr 2025, 21:54 UTC

Tulu

Becton Dickinson Sees 2025 EPS $14.30-EPS $14.60 >BDX

5. veebr 2025, 21:54 UTC

Tulu

Becton Dickinson Sees 2025 GAAP Rev Growth 7.9% to 8.4% >BDX

5. veebr 2025, 21:53 UTC

Tulu

Becton Dickinson Sees 2025 Rev $21.7B-$21.9B >BDX

5. veebr 2025, 21:30 UTC

Tulu

Becton Dickinson 1Q Adj EPS $3.43 >BDX

5. veebr 2025, 21:30 UTC

Tulu

Becton Dickinson 1Q Rev $5.2B >BDX

5. veebr 2025, 21:30 UTC

Tulu

Becton Dickinson 1Q Net $303M >BDX

5. veebr 2025, 21:30 UTC

Tulu

Becton Dickinson 1Q EPS $1.04 >BDX

7. nov 2024, 11:36 UTC

Tulu

Becton Dickinson Sees FY25 Rev $21.9B-$22.1B >BDX

7. nov 2024, 11:35 UTC

Tulu

Becton Dickinson Sees FY25 Adj EPS $14.25-Adj EPS $14.60 >BDX

7. nov 2024, 11:30 UTC

Tulu

Becton Dickinson 4Q EPS $1.45 >BDX

7. nov 2024, 11:30 UTC

Tulu

Becton Dickinson 4Q Adj EPS $3.81 >BDX

7. nov 2024, 11:30 UTC

Tulu

Becton Dickinson 4Q Rev $5.4B >BDX

7. nov 2024, 11:30 UTC

Tulu

Becton Dickinson 4Q Cont Ops EPS $1.45 >BDX

1. aug 2024, 10:37 UTC

Tulu

Becton Dickinson Now Sees FY24 Revenue About $20.1B; Had Seen $20.1B-$20.3B >BDX

1. aug 2024, 10:35 UTC

Tulu

Becton Dickinson Sees FY24 Revenue Up About 3.7%, Organic Revenue Up 5%-5.25% >BDX

1. aug 2024, 10:35 UTC

Tulu

Becton Dickinson Sees FY24 Adj EPS $13.05-Adj EPS $13.15 >BDX

1. aug 2024, 10:30 UTC

Tulu

Becton Dickinson 3Q EPS $1.68 >BDX

1. aug 2024, 10:30 UTC

Tulu

Becton Dickinson 3Q Net $487M >BDX

1. aug 2024, 10:30 UTC

Tulu

Becton Dickinson 3Q Adj EPS $3.50 >BDX

1. aug 2024, 10:30 UTC

Tulu

Becton Dickinson 3Q Rev $5B >BDX

4. juuni 2024, 17:26 UTC

Omandamised, ülevõtmised, äriostud

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3. juuni 2024, 15:30 UTC

Kuumad aktsiad

Stocks to Watch Monday: GameStop, AMC, Paramount, Nvidia -- WSJ

3. juuni 2024, 13:26 UTC

Omandamised, ülevõtmised, äriostud

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3. juuni 2024, 12:25 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

Võrdlus sarnastega

Hinnamuutus

Becton Dickinson and Co Prognoos

Hinnasiht

By TipRanks

19.62% tõus

12 kuu keskmine prognoos

Keskmine 274 USD  19.62%

Kõrge 280 USD

Madal 260 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Becton Dickinson and Co 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

9

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

227.83 / 230.0625Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

18 / 386 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.